A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)
Sponsor: |
AstraZeneca AB |
Enrolling: |
Female Patients Only |
IRB Number: |
AAAS3988 |
U.S. Govt. ID: |
NCT03830866 |
Contact: |
Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu |
AstraZeneca AB (AstraZeneca) is doing this research to find out if durvalumab, when given with chemoradiotherapy will help to treat cervical cancer.
This study is closed
Investigator
Ana Tergas, MD
Have you been diagnosed with cervical cancer? |
Yes |
No |